Submitted by Anonymous (not verified) on 27 May 2026 - 14:22
Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised